References
- Mehraeen E, Salehi MA, Behnezhad F, et al. Transmission modes of COVID-19: a systematic review. Infect Disord Drug Targets. 2021;21(6):e1077503845. doi:10.2174/22123989MTExjNTEn0
- Awad M, Al-Hussaniy HA, Alburghaif AH, et al. The role of COVID-19 in myopathy: incidence, causes, treatment, and prevention. J Med Life. 2022;15(12):1458–1463. doi:10.25122/jml-2022-0167
- Focosi D, Quiroga R, McConnell S, et al. Convergent evolution in SARS-CoV-2 spike creates a variant soup from which new COVID-19 waves emerge. Int J Mol Sci. 2023;24(3):2264. doi:10.3390/ijms24032264
- Ethirajan T, Natarajan G, Velayudham R, et al. Clinico-epidemiological profile of COVID-19 patients with Omicron variant admitted in a tertiary care center, South India. Int J Gen Med. 2023;16:185–191. doi:10.2147/IJGM.S365207
- Migueres M, Dimeglio C, Tremeaux P, et al. Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant. J Infect. 2022;84(4):e7–e9. doi:10.1016/j.jinf.2022.01.036
- Kupferschmidt K. Where did ‘weird’ Omicron come from? Science. 2021;374(6572):1179. doi:10.1126/science.acx9738
- Pulliam J, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376(6593):n4947. doi:10.1126/science.abn4947
- Bastard J, Taisne B, Figoni J, et al. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022. Euro Surveill. 2022;27(13). doi:10.2807/1560-7917.ES.2022.27.13.2200247
- Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30(8):1077–1083. doi:10.1016/j.chom.2022.05.001
- Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437–446. doi:10.1016/S0140-6736(22)00017-4
- CDC Weekly C. The epidemiological characteristics of an outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Wkly. 2020;2(8):113–122. doi:10.46234/ccdcw2020.032
- Ataei A, Derakhshan MM, Razmjooie M, et al. Androgens’ role in severity and mortality rates of COVID-19. Horm Metab Res. 2022;54(12):813–826. doi:10.1055/a-1954-5605
- Borgoni S, Kudryashova KS, Burka K, et al. Targeting immune dysfunction in aging. Ageing Res Rev. 2021;70:101410. doi:10.1016/j.arr.2021.101410
- Chen Y, Li C, Liu F, et al. Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerg Microbes Infect. 2022;11(1):368–383. doi:10.1080/22221751.2022.2026741
- DeSantis SM, Yaseen A, Hao T, et al. Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: a population-based survey of 22,575 participants. J Infect Dis. 2023;227:1164–1172. doi:10.1093/infdis/jiad020
- Jansen L, Tegomoh B, Lange K, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) variant cluster - Nebraska, November-December 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1782–1784. doi:10.15585/mmwr.mm705152e3
- Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020;285:198005. doi:10.1016/j.virusres.2020.198005
- Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395–1399. doi:10.1016/j.cmi.2020.06.025
- Nowak MD, Sordillo EM, Gitman MR, et al. Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? J Med Virol. 2020;92(10):1699–1700. doi:10.1002/jmv.25953